We are preparing the requested document. Please wait, this may take a while...!
|Antigène||Progesterone Receptor (PGR) Anticorps|
|Épitope||AA 412-526 Alternatives|
|Conjugué||Cet anticorp Progesterone Receptor est non-conjugé Alternatives|
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Détail du produit anti-Progesterone Receptor anticorpsDétail du antigène Progesterone Receptor Information d'application Stockage Images
|Fonction||This antibody is designed for the specific localization of human PR using IHC techniques in formalin-fixed, paraffin- embedded tissue sections.|
|Attributs du produit||The determination of steroid hormone receptors is of great importance for therapy of patients with hormone receptor expressing tumours. Progesterone and estrogen receptor positive breast carcinoma patients have demonstrated a better response to endocrine therapy than receptor negative patients. Expression of progesterone receptors in tumour cells of human breast carcinoma points to an intact estrogen receptor and to sensitivity of this tumour to endocrine therapy. Several investigations have shown that progesterone receptor is a better prognostic marker than estrogen receptor. Immunohistochemistry (IHC) is a complex technique in which immunological and histological detection methods are combined. In general, the manipulation and processing of tissues before immunostaining, especially different types of tissue fixation and embedding, as well as the nature of the tissues themselves may cause inconsistent results (Nadji and Morales, 1983). Endogenous pseudoperoxidase and peroxidase activity or endogenous biotin and alkaline phosphatase activity can cause non-specific staining results depending on the detection system used. Tissues that contain Hepatitis B surface antigen (HBsAg) can produce false positives when using HRP detection systems (Omata et al, 1980). Insufficient contrast staining and/or improper mounting of the sample may influence the interpretation of results.|
|Purification||Ready-to-use, Prediluted, obtained from culture supernatant|
|Matériel non inclus||All reagents, materials, and laboratory equipment for IHC procedures are not provided with this antibody. This includes adhesive slides and cover slips, positive and negative control tissues, Xylene or adequate substitute, ethanol, distilled H2O, heat pretreatment equipment (pressure cooker, steamer, microwave), pipettes, Coplin jars, glass jars, moist chamber, histological baths, negative control reagents, counter-staining solution, mounting materials, and microscope.|
|Immunogène||Recombinant protein corresponding to amino acid residues 412-526 of human PR.|
|Plasmids, Primers & others|
Détail du antigène Progesterone ReceptorDétail du produit anti-Progesterone Receptor anticorps Information d'application Stockage Images Haut de la page
|Autre désignation||Progesterone Receptor (PGR Antibody Extrait)|
|Pathways||Nuclear Receptor Transcription Pathway, Intracellular Steroid Hormone Receptor Signaling Pathway, Steroid Hormone Mediated Signaling Pathway, Smooth Muscle Cell Migration|
Information d'applicationDétail du produit anti-Progesterone Receptor anticorps Détail du antigène Progesterone Receptor Stockage Images Haut de la page
Staining pattern: Nuclear. The interpretation of the stain results is the full responsibility of the user. Any experimental result must be confirmed by a medically established diagnostic product or procedure.
Principles of the procedure: The demonstrations of antigens by IHC is a sequential procedure with several steps involving first the application of a specific antibody for the antigen of interest (primary antibody), then a secondary antibody which joins to the first, an enzyme complex, and the addition of a chromogenic substrate. The sample is washed between each step. Enzymatic activation of the chromogenic substrate creates a visible product where the antigen is located. The results are interpreted using a light microscope. The primary antibody can be used both in manual IHC and with automated immunostainers.
Paraffin-embedded tissue samples should be used. The antibody is also useful for immunostaining frozen tissue samples. Western blot techniques are not recommended.
|Procédure de l'essai||
Antigen retrieval: HIER Citrate Buffer pH 6.5
Working dilution: (only for concentrates) 1:50 – 1:200
Incubation: 30 min, RT
Control Tissue: Breast carcinoma
|Restrictions||For Research Use only|
StockageDétail du produit anti-Progesterone Receptor anticorps Détail du antigène Progesterone Receptor Information d'application Images Haut de la page
|Buffer||The preparation contains saline buffer, stabilising and carriers proteins. (pH 7.4)|
|Agent conservateur||Sodium azide|
|Précaution d'utilisation||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Stockage commentaire||Store at 2-8 °C until the expiration date printed on product label. Do not use after the expiration date. If fresh solutions are required, these must be prepared immediately prior to use, and will be stable for at least one day at room temperature (20-25°C). Unused portion of antibody preparation should be discarded after one day.If the product is stored under different conditions from those stipulated in these technical indications, the new conditions must be verified by the user. The validity period of the ready to use products when opened, is the same as the expiration date indicated on the label of intact product.|
ImagesDétail du produit anti-Progesterone Receptor anticorps Détail du antigène Progesterone Receptor Information d'application Stockage Haut de la page